163 related articles for article (PubMed ID: 29511553)
1. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease.
Kirstein MM; Voigtländer T; Schweitzer N; Hinrichs JB; Marquardt J; Wörns MA; Kloeckner R; Fründt TW; Ittrich H; Wacker F; Rodt T; Manns MP; Wege H; Weinmann A; Vogel A
United European Gastroenterol J; 2018 Mar; 6(2):238-246. PubMed ID: 29511553
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
3. Identifying optimal candidates of transarterial chemoembolization (TACE)
Zhao S; Dou W; Fan Q; Hu J; Li H; Zhang X; Zhang Q; Liu L
Ann Transl Med; 2020 May; 8(9):587. PubMed ID: 32566614
[TBL] [Abstract][Full Text] [Related]
4. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study.
Peng TR; Wu TW; Wu CC; Chang SY; Chan CY; Hsu CS
Tzu Chi Med J; 2022; 34(2):219-225. PubMed ID: 35465280
[TBL] [Abstract][Full Text] [Related]
8. Transarterial Chemoembolization (TACE) Combined with Sorafenib
Ren B; Wang W; Shen J; Li W; Ni C; Zhu X
J Cancer; 2019; 10(5):1189-1196. PubMed ID: 30854128
[No Abstract] [Full Text] [Related]
9. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC
Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
Cao Y; Ouyang T; Xiong F; Kan X; Chen L; Liang B; Zheng C
Hepatol Int; 2021 Oct; 15(5):1268-1277. PubMed ID: 34415515
[TBL] [Abstract][Full Text] [Related]
11. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study.
Patidar Y; Chandel K; Condati NK; Srinivasan SV; Mukund A; Sarin SK
J Clin Exp Hepatol; 2022; 12(3):745-754. PubMed ID: 35677519
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
13. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis.
Chu HH; Kim JH; Shim JH; Yoon SM; Kim PH; Alrashidi I
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365655
[TBL] [Abstract][Full Text] [Related]
14. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib Combined with Chemoembolization for Locally Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score Analysis.
Kim GH; Choi SL; Kim JH; Shim JH; Alali M; Kim N
Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685437
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study.
Yuan J; Yin X; Tang B; Ma H; Zhang L; Li L; Chen R; Xie X; Ren Z
Biomed Res Int; 2019; 2019():2141859. PubMed ID: 31467872
[TBL] [Abstract][Full Text] [Related]
17. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
18. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice.
Li S; Mei J; Wang Q; Shi F; Liu H; Zhao M; Lu L; Ling Y; Guo Z; Guo Y; Chen X; Shi M; Lau WY; Wei W; Guo R
Hepatobiliary Surg Nutr; 2021 Oct; 10(5):631-645. PubMed ID: 34760967
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study.
Qiu Z; Shen L; Jiang Y; Qiu J; Xu Z; Shi M; Yu Z; Ma Y; He W; Zheng Y; Li B; Wang G; Yuan Y
Ann Transl Med; 2021 Feb; 9(4):283. PubMed ID: 33708910
[TBL] [Abstract][Full Text] [Related]
20. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
Yin L; Liu KC; Lv WF; Lu D; Tan YL; Wang GX; Dai JY; Zhu XH; Jiang B
Cancer Imaging; 2023 May; 23(1):52. PubMed ID: 37254146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
